Search results for "Survivor"

showing 10 items of 184 documents

Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort

2022

Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow-up care. Methods: Population-based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15-39 years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5 years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs. Results: The cohort included 67,692 A…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyAdolescentColorectal cancercancer survivorPopulationBreast NeoplasmsSettore MED/42 - Igiene Generale E ApplicataProstate cancerBreast cancerRisk FactorsInternal medicineNeoplasmsfollow-upMedicineHumanscancer survivorsCumulative incidenceadolescentseducationLung cancerRetrospective Studieseducation.field_of_studyBladder cancerbusiness.industryIncidenceCancerregistriesNeoplasms Second Primarymedicine.diseasehumanitiesregistrieOncologyadolescents cancer survivors follow-up registries young adultyoung adultFemalebusiness
researchProduct

The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of …

2008

The aim of this study was to provide further quantitative data on the risk of second nonmelanoma cancers in patients with cutaneous malignant melanoma (CMM). A cohort of 14 560 population-based patients from the Italian Network of Cancer Registries incident during 1985-2002 were included and followed up for further incident cases and vital status. Standardized incidence ratios (SIR) were used to compare the number of observed second cancers with expected cancers. In a total of 69 581 person-years, 1020 second cancers were registered, of which 804.6 were expected (SIR=1.27; 95% confidence interval 1.19-1.35). The risk was similar for males and females, (SIR=1.27 and 1.26, respectively). The …

OncologyAdultMaleCancer Researchmedicine.medical_specialtySkin NeoplasmsSettore MED/06 - Oncologia MedicaPopulationDermatologyCohort StudiesRisk FactorsInternal medicineEpidemiology of cancerMedicineHumansRegistriesSurvivorseducationMelanomaAgedAged 80 and overeducation.field_of_studybusiness.industryIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseasehumanitiesConfidence intervalcutaneous melanomacancerOncologyItalyCohortCutaneous melanomaFemalesecond cancer - survivors - malignant melanomabusinessCohort studyFollow-Up StudiesMelanoma research
researchProduct

Cancer: New Needs, New Models. Is It Time for a Community Oncologist? Another Brick in the Wall

2021

Simple Summary Community care activity in the oncology field does not exist. This unmet need contrasts with the increasing number of patients with a previous diagnosis of cancer. Abstract Over the last few decades, thanks to early detection, effective drugs, and personalized treatments, the natural history of cancer has radically changed. Thanks to these advances, we have observed how survival of cancer patients has increased, becoming an ever more important goal in cancer care. Effective clinical governance of survivorship care is essential to ensure a successful transition between active and post-treatment life, identifying optimization of healthcare outcomes and quality of life for patie…

OncologyCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaEarly detectionSettore MED/42 - Igiene Generale E Applicataclinical governance03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Internal medicineSurvivorship curveIntervention (counseling)Health caremedicine030212 general & internal medicineRC254-282Clinical governancebusiness.industryCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasecommunity oncologyNatural historycancer survivorshipOncology030220 oncology & carcinogenesisPerspectivebusinessPsychologyCancers
researchProduct

Genetic determinants of ototoxicity during and after childhood cancer treatment: Protocol for the pancarelife study

2019

BACKGROUND: Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a common adverse effect in children treated with cisplatin-based chemotherapy or cranial radiotherapy. Ototoxicity can extend from high-tone hearing impairment to involvement of speech frequencies. Hearing impairment can impede speech and language and neurocognitive development. Although treatment-related risk factors for hearing loss following childhood cancer treatment have been identified, the individual variability in toxicity of…

OncologyCandidate gene020205 medical informaticscisplatinCHILDREN02 engineering and technologyVARIANTSPLATINUM-INDUCED OTOTOXICITYChildhood cancer survivors0302 clinical medicineTPMT0202 electrical engineering electronic engineering information engineeringProtocolGWASgenetics030212 general & internal medicineSURVIVORSGeneral MedicineCHEMOTHERAPY3. Good healthototoxicityCohortmedicine.symptomcandidate genes020 Library & information sciencesmedicine.medical_specialtyINDUCED HEARING-LOSSHearing losschildhood cancer survivors610 Medicine & healthINTERNATIONAL SOCIETYCandidate genes03 medical and health sciencesACYP2OtotoxicitySDG 3 - Good Health and Well-being360 Social problems & social servicesInternal medicinemedicineGenetic predispositionGeneticsCISPLATIN-INDUCED OTOTOXICITYAdverse effecthearing lossbusiness.industryCancerHearing lossmedicine.diseaseOtotoxicityClinical trialCisplatinbusinessPolymorphismspolymorphisms
researchProduct

Association of candidate pharmacogenetic markers with platinum-induced ototoxicity

2020

Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in a pharmacogenetic guideline. The PanCareLIFE cross-sectional cohort study evaluated the genetic associations in a large pan-European population and assessed the diagnostic accuracy of the genetic markers. 1,112 pediatric cancer survivors who had provided biomaterial for genotyping were screened for participation in the pharmacogenetic association study. 900 participants qualified for inclusion. Based on the assessment of original audiograms, patien…

OncologyDrug-induced ototoxicitymedicine.medical_specialtyCandidate geneHearing lossMulticenter cohort studyCancer survivorsPopulationAdverse drug reaction610 Medicine & healthlcsh:Computer applications to medicine. Medical informatics03 medical and health sciences0302 clinical medicine360 Social problems & social servicesInternal medicinemedicineGenetic predisposition610 Medicine & healtheducationlcsh:Science (General)030304 developmental biologyGenetic association0303 health scienceseducation.field_of_studyMultidisciplinaryThiopurine methyltransferasebiologycarboplatin [Cisplatin]business.industryMedicine and DentistryPediatric cancerCisplatin: carboplatinPharmacogeneticsbiology.proteinlcsh:R858-859.7Genetic markersmedicine.symptombusinessChildhood cancer360 Social problems & social services030217 neurology & neurosurgeryPharmacogeneticslcsh:Q1-390Data in brief
researchProduct

Effect of genetic variation in CYP450 on Gonadal impairment in a European cohort of female childhood cancer survivors, based on a candidate gene appr…

2021

Background: Female childhood cancer survivors (CCSs) carry a risk of therapy-related gonadal dysfunction. Alkylating agents (AA) are well-established risk factors, yet inter-individual variability in ovarian function is observed. Polymorphisms in CYP450 enzymes may explain this variability in AA-induced ovarian damage. We aimed to evaluate associations between previously identified genetic polymorphisms in CYP450 enzymes and AA-related ovarian function among adult CCSs. Methods: Anti-Müllerian hormone (AMH) levels served as a proxy for ovarian function in a discovery cohort of adult female CCSs, from the pan-European PanCareLIFE cohort (n = 743

OncologyInfertilityCancer ResearchCandidate genemedicine.medical_specialtyendocrine systemendocrine system diseasesMedizinAnti-Müllerian hormoneArticleHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Childhood cancer survivors03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingInterquartile rangeInternal medicineGenetic variationGenetic modelmedicineChemotherapyFertility preservationRC254-282030304 developmental biology0303 health sciencesbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensAnti-Müllerian hormonemedicine.diseaseOvarian functionCytochrome P450 genesWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthOncology030220 oncology & carcinogenesisCohortbiology.proteinCandidate gene approachbusinessGeneral Economics Econometrics and FinanceCancers
researchProduct

Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas.

2020

Background The occurrence of prior, concurrent and subsequent neoplasms (SN) represents a serious problem in children and adolescents with soft tissue sarcomas. Pathogenic germline variants contribute to the diagnosis of multiple neoplasms in sarcoma survivors. Materials and methods The records of 748 children and adolescents, diagnosed with soft tissue sarcomas and registered in trials/registries by the cooperative soft tissue sarcoma (Cooperative Weichteilsarkom Studie) group, were reviewed for the occurrence of SNs. Reference histology review was available for all cases; the presence of oncogenic fusions known at the time of diagnosis was confirmed for fusion-positive (F+) entities. Resu…

OncologyMalemedicine.medical_specialtyAdolescentOncogene Proteins FusionGermline03 medical and health sciences0302 clinical medicineCancer SurvivorsRisk FactorsInternal medicineGermanyBiomarkers TumorMedicineHumansRegistriesNeurofibromatosisChildGerm-Line MutationClinical Trials as Topicbusiness.industryIncidence (epidemiology)Soft tissue sarcomaIncidenceSoft tissueInfantHistologyNeoplasms Second PrimarySarcomaHematologymedicine.diseasePrognosisCombined Modality TherapySurvival RateOncology030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemaleSarcomabusiness030215 immunologyFollow-Up StudiesJournal of pediatric hematology/oncology
researchProduct

European Society for Medical Oncology (ESMO) position paper on supportive and palliative care

2018

Oncology has come a long way in addressing patients' quality of life, together with developing surgical, radio-oncological and medical anticancer therapies. However, the multiple and varying needs of patients are still not beingmet adequately as part of routine cancer care. Supportive and palliative care interventions should be integrated, dynamic, personalised and based on best evidence. They should start at the time of diagnosis and continue through to end-of-life or survivorship. ESMO is committed to excellence in all aspects of oncological care during the continuum of the cancer experience. Following the 2003 ESMO stand on supportive and palliative care (Cherny N, Catane R, Kosmidis P. …

Oncologymedicine.medical_specialtyPalliative caremedia_common.quotation_subjectPatient-Centered Care/methodsPsychological interventionPatient-centred care03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Multidisciplinary approachExcellenceInternal medicineSurvivorship curveNeoplasmsPatient-Centered CaremedicineNeoplasms/therapyHumansPosition paper030212 general & internal medicinemedia_commonPalliative Care/methodsTerminal Carebusiness.industryPalliative CareCancerHematologyESMOmedicine.diseaseTerminal Care/methodsMultidisciplinarityOncology030220 oncology & carcinogenesisPractice Guidelines as TopicPalliative careQuality of LifePosition paperbusinessSupportive care
researchProduct

Dinosaurian survivorship schedules revisited: new insights from an age‐structured population model

2021

Little is known of dinosaur population biology due to insufficient information on age‐dependent fecundities and mortalities. So far, survivorship curves (SC) of only six dinosaurs (four tyrannosaurs, one ceratopsian, one hadrosaur) have been erected from bone assemblages of aged specimens. They indicate high survival throughout most of their life with presumably higher mortalities after hatching and increasing mortalities towards its end. However, none of these studies recognized that to infer a reliable SC for a taxon, the assemblage must preserve a stationary age distribution (i.e. one which is stable, with constant population size over time as overall fecundities match mortalities, herea…

PaleontologyAge structureSurvivorship curvePaleontologyddc:567.91BiologyFecundityEcology Evolution Behavior and SystematicsDemographyLife history theory
researchProduct

Late Cardiac Events after Childhood Cancer: Methodological Aspects of the Pan-European Study PanCareSurFup.

2016

Background and AimChildhood cancer survivors are at high risk of long-term adverse effects of cancer and its treatment, including cardiac events. The pan-European PanCareSurFup study determined the incidence and risk factors for cardiac events among childhood cancer survivors. The aim of this article is to describe the methodology of the cardiac cohort and nested case-control study within PanCareSurFup.MethodsEight data providers in Europe participating in PanCareSurFup identified and validated symptomatic cardiac events in their cohorts of childhood cancer survivors. Data on symptomatic heart failure, ischemia, pericarditis, valvular disease and arrhythmia were collected and graded accordi…

PediatricsCritical Care and Emergency MedicineCancer Treatmentlcsh:MedicineADULT SURVIVORSCHILDREN030204 cardiovascular system & hematologyDOXORUBICIN THERAPYPediatricsCohort Studies0302 clinical medicineRisk FactorsNeoplasmsMedicine and Health SciencesSurvivorsYoung adultChildlcsh:Scienceeducation.field_of_studyMultidisciplinaryGUIDELINE HARMONIZATION GROUPCancer Risk Factors3. Good healthEuropeOncologyHelminth Infections030220 oncology & carcinogenesisChild PreschoolCohortHEALTH OUTCOMESRecord linkageCohort studyResearch ArticleNeglected Tropical DiseasesAdultCARDIOTOXICITYmedicine.medical_specialtyAdolescentHeart DiseasesLONG-TERMPopulationCardiology610 Medicine & health03 medical and health sciencesYoung Adult360 Social problems & social servicesDiagnostic MedicineEchinococcosismedicineCancer Detection and DiagnosisParasitic DiseasesHumanseducationAdverse effectCONGESTIVE-HEART-FAILUREbusiness.industryMORTALITYlcsh:RCase-control studyCancerInfantmedicine.diseaseTropical DiseasesPediatric OncologyCase-Control StudiesRISK-FACTORSlcsh:QbusinessPLoS ONE
researchProduct